Resources
-
Development of mRNA-LNP Manufacturing Process Platform
Speaker Presentation: Symposium on mRNA 2025
Luthra Sumit, Sanofi, 2025 -
Establishing Quality Benchmarks: Platform
Technology Approach to mRNA Product Quality
Speaker Presentation: Symposium on mRNA 2025
Kattel Sarita, US Pharmacopeia, 2025 -
Early Regulatory Considerations for RNA Therapies for Rare Diseases
Speaker Presentation: Symposium on mRNA 2025
Hagan Julie, Korro Bio, 2025 -
Analytical Comparability of mRNA Vaccines: Supporting the
Global Rollout of Comirnaty® and Streamlining the Strategy for
the mRNA Vaccine Pipeline
Speaker Presentation: Symposium on mRNA 2025
Eschmann Neil, Pfizer, Inc., 2025 -
A Trailblazing Digital
Approach Coupled with
PAT-Enabled Rapid
Manufacturing from MIT
and ReciBiopharm (Case
Study No. 01 xRNA)
Speaker Presentation: Symposium on mRNA 2025
Cowley Aaron, ReciBioPharm, 2025 -
A to Z of IVE: From Single Antigen to Multiplex Flow Cytometry and LC-MS/MS
Speaker Presentation: Symposium on mRNA 2025
Byrne Emilia, Pfizer, Inc., 2025 -
Streamlining Analytical Platform Procedures:
Addressing Early Phase Development Challenges
Speaker Presentation: Virtual Europe Discussion Group 2025
Eggink Mark, Byondis, 2025 -
Retrospective Establishment of Platform
Analytical Procedures
Speaker Presentation: Virtual Europe Discussion Group 2025
Milford Mark, Eli Lilly and Company, 2025 -
Commercial Submission Considerations for Platform Analytical Procedures
Speaker Presentation: Virtual Europe Discussion Group 2025
Rule Karen, Pfizer, Inc., 2025 -
Comparability of
Alternative
Procedures
Speaker Presentation: Netherlands Area Biotech Discussion Group 2025
Spieldenner Bruno, EDQM, 2025 -
IQ Biologics Specifications Setting Challenges and Opportunities Working Group Endotoxin Subgroup Readout
Speaker Presentation: CMC Strategy Forum North America 2025
Kearns Katrina, Pfizer, Inc., 2025 -
Bridges Over Multiple Biotech Corridors
Speaker Presentation: Bioassays 2025
Weil Dylan, AstraZeneca, 2025 -
Afucosylation:
Potency Evaluation Strategies
Speaker Presentation: Bioassays 2025
Swiss Victoria, Bristol-Myers Squibb Company, 2025 -
Development of a New Class of Target Cell Lines to Evaluate Fc-mediated Cytotoxicity
Speaker Presentation: Bioassays 2025
Vendor Showcase, Svar Life Science, 2025 -
PLA 3.0 – Latest Developments
Speaker Presentation: Bioassays 2025
Vendor Showcase, Stegmann Systems, 2025 -
Quantitative Cellular PAT Analytics Driving Improvements in Advanced Therapy Process and Production Outcomes
Speaker Presentation: Bioassays 2025
Vendor Showcase, LumaCyte, Inc., 2025 -
DPX Technologies - Delivering Purification Excellence
Speaker Presentation: Bioassays 2025
Vendor Showcase, DPX Technologies, 2025 -
We are Catalent
Speaker Presentation: Bioassays 2025
Vendor Showcase, Catalent, 2025 -
BioAgilytix - Global Footprint, Local Resources
Speaker Presentation: Bioassays 2025
Vendor Showcase, BioAgilytix, 2025 -
5 Good Reasons to Use Assay Ready InstaCELLs
Speaker Presentation: Bioassays 2025
Vendor Showcase, acCELLerate, 2025